Essentials of the FDA Landscape for Patient Organizations

Overview

Learn the essentials of drug and device law and how to engage with FDA to better support your organization’s advocacy efforts.

For this two-day virtual program, FDLI brings together law, industry, and FDA experts with deep advocacy experience to equip patient organizations with an understanding of the legal tools and strategies available for interacting with the agency. Case studies will illustrate the opportunities for engagement and legal challenges facing patient organizations, and there will be ample opportunity to get your questions answered. Ahead of the live course, complete the ProgressForPatients.org Advocacy Education Program for background information and to prepare for the live sessions.

Sponsors

Sponsorship opportunities are available. Please let us know if you would like more information.

Gold

Silver

A special thanks to the FDLI Patient Organization Engagement Committee:

Mitchell Berger, HHS
Ryan Hohman, Friends of Cancer Research
Kira Jabri, EMMA International
Susan S. Lee, Goodwin Procter LLP
Katherine Maynard, Peterson Wilmarth and Robertson, LLP (PWR)
Christopher M. Mikson, DLA Piper LLP (US)
Natalie Oehlers, Buchanan Ingersoll & Rooney PC
Amirala Pasha, Mayo Clinic
Peter Pitts, Center for Medicine in the Public Interest
James E. Valentine, Hyman, Phelps & McNamara, PC
Jessica Vaughn, Wiley LLP
David Zook, Faegre Drinker Biddle & Reath LLP

Essentials of the FDA Landscape for Patient Organizations

Partners